ClinicalTrials.gg
RecruitingNCT05853861PETALUpdated Mar 31, 2026

Promoting Early Intervention Timing and Attention to Language

An interventional study of JASPER Babble in MONITOR and COACH, sponsored by University of California, Los Angeles. Recruiting at 2 sites in United States. Open to participants aged 6 Months to 8 Months. Per ClinicalTrials.gov, last updated 2026-03-31.

Sponsored by University of California, Los Angeles · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2024; still recruiting 1 year 11 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
6 Months to 8 Months
Sex
All
01

Study summary

The proposed study (PETAL: Promoting Early intervention Timing and Attention to Language) aims to determine the timing of intervention among infants with Increased Likelihood for Autism (ILA; at risk for autism by virtue of having an older sibling with autism) on communication and language outcomes at 24 months. Results of this study will determine when (9 vs 12 vs 15 months), and based on which measures (brain, language, or their combination) to augment parental support with a specialized parent-mediated coaching intervention for optimal outcomes on communication and language at 24 months.

Children will be recruited at 6-8 months of age and will begin with entry assessments. All children will first begin with the MONITOR condition (using Ages \& Stages Questionnaire (ASQ-3) and activity cards. Then when the child is 9 months, they will be randomized to continue with MONITOR condition or COACH condition (i.e. JASPER Babble) after second set of assessments. There are a total of 6 assessment timepoints (6-8 months of age, 9 months of age, 12 months of age, 15 months of age, 18 months of age, and 24 months of age). At time points of 9months and 12 months, the child will be randomized to COACH or MONITOR conditions. Once the child is randomized to COACH condition, they will continue with that condition until they terminate the study at 24 months. At the 15 months timepoint, there will no longer be a randomization. Children that were in the MONITOR condition will change to the COACH condition until they terminate the study.

Read the detailed description

A total of 140 infants aged 6-8 months old who are siblings of children with ASD will participate, with an expected 30-60infants recruited each year for 3 years. We expect to recruit a diverse sample of ILA infants and families in two sites, Los Angeles area and Boston area; many will be from traditionally marginalized and minoritized families, mostly low income. Referrals will be elicited from community partners with which both sites have a long history, including school systems, federally qualified health centers, local clinics, family resource centers, and family support groups.

This study will use a four phase, Sequential Multiple Assignment Randomized Trial (SMART) design to examine the effectiveness of transitioning to more intensive early intervention prior to 15 months of age, and to inform clinical decision-making concerning the optimal time to transition to more intensive intervention based on the specific characteristics of the child. Phase 1 begins at age 6 months; after baseline demographic, language, behavior and brain assessments, all children are offered the MONITOR intervention. Phase 2 begins at age 9 months; after language, behavior and brain assessments, all children are randomly assigned to transition to MONITOR plus COACH (with probability 1/3) versus continue with MONITOR (with probability 2/3). Phase 3 begins at age 12 months; following language, behavior, and brain assessments, children who have not yet transitioned to MONITOR plus COACH are randomly assigned (with equal probability) to transition to MONITOR plus COACH versus continue with MONITOR. Phase 4 begins at age 15 months; following language and behavior assessments, all remaining children will transition to MONITOR plus COACH.

The MONITOR condition consists will take a global, general domain approach to providing parents with information to track the early development of their infants, along with specific developmentally targeted activities. The well validated Ages and Stages-3+ screening tool along with activity cards will provide information to parents at each age. All parents will receive these materials at 3-month intervals, along with a developmentally chosen toy and book for their infant. We will provide an appropriate toy/book given we expect a diverse sample including many low resourced families. The questionnaire takes 10- 15 minutes to complete and covers developmental domains of communication, motor, problem-solving and personal-social, and is available in English, Spanish, and several other languages. We will drop off or mail the specific form and activity card (plus toy and book) to families at each of our specified ages---6, 9, 12, 15, 18, 21 and 24months. The intervention activities card includes suggestions for games and other fun events for parent- infant dyads. Moreover, each family will have access to the intervention team (text, call, zoom) on an as needed protocol, and we will keep track of all contact. The MONITOR intervention continues for all infants and parents throughout the study period even after receiving COACH intervention.

The COACH condition consists of JASPER Babble, which is an evidence-based intervention. Infant-parent dyads will be randomized to receive COACH (JASPER Babble) at 9, 12 or 15 months. JASPER Babble addresses early parent-child social communication by helping to close the 'feedback loop'. When parents talk and play with their infant, the infant increases their developmental behaviors which serve to provide more opportunities for parents to respond. JASPER Babble targets on babbling specifically will be incorporated into this feedback loop, and the importance of the blended intervention should be underscored, providing both context and targets. For infant-parentdyads randomized to COACH, we will set up once weekly remote (zoom) 1-hour coaching sessions in between assessment visits each 3 months. Similar to the ASQ-3+ monitoring intervention, parents will have access to the intervention team on as needed basis throughout the study if they request more input, and we will track this contact. Once randomized to COACH, parents will continue to receive the remotely delivered intervention throughout the study period.

Assessments will be administered at 6 timepoints. At entry (when child is 6-8 months), parents will sign consent, fill out demographic forms, treatment history form, Mullen, PCX, LENA, and EEG.

At the 9 months and 12 months timepoints, the Mullen, PCX, LENA, and EEG will be administered again.

At 15, 18, and 24 months, the Mullen, PCX, LENA will be administered. An ADOS-2 will also be administered at 24months only.

02

Conditions studied

  • MONITOR
  • COACH

Keywords

  • autism
  • siblings
  • JASPER
  • speech
  • intervention
03

In context

Autistic Disorder

1,030 studies on the registry are indexed under Autistic Disorder; 266 are open to participants now.

This study's planned enrollment of 140 is above the median of 49 across 811 interventional studies indexed under Autistic Disorder.

Browse Autistic Disorder studies →

Lead sponsor

University of California, Los Angeles is the lead sponsor of 1,170 studies on the registry; 195 are open to participants now.

Of its 95 completed or terminated interventional studies of FDA-regulated products, 70 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Months to 8 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • This study will recruit approximately 140 infants ages 6-8 months of age who are younger siblings of children with ASD.
  • Both males and females are eligible for study participation and will be recruited.
  • Family income is under the very low income described under the Department of Housing and Community DevelopmentDivision of Housing Policy Agreement for the city of Los Angeles.

Exclusion criteria

Exclusion Criteria:

  • Infants who have seizures and are not stable on anti-seizure medication
  • Infant is expected to have surgery over the next year
  • Infant has associated physical disorders, and/or co-morbid with other syndromes or diseases.
  • All of the children will be free of additional sensory or motor impairments (e.g., Visual or hearing impairment) and othergenetic syndromes (e.g., Down Syndrome).
  • In addition, infants who are premature or less than 34 weeks (gestational age \<34 weeks) will be excluded.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
140 participants (estimated)

Study arms

  • Experimental
    9 month coaching

    Participants receive JASPER Babble coaching at 9 months of age. Prior to 9 months, participants are just being monitored.

    Behavioral: JASPER Babble

  • Experimental
    12 month coaching

    Participants receive JASPER Babble coaching at 12 months of age. Prior to 12 months, participants are just being monitored.

    Behavioral: JASPER Babble

  • Experimental
    15 month coaching

    Participants receive JASPER Babble coaching at 15 months of age. Prior to 15 months, participants are just being monitored.

    Behavioral: JASPER Babble

Interventions

  • BehavioralJASPER Babble

    JASPER Babble is an evidence based early intervention that focuses on the core social communication and engagement skills of young children that are important to improvements in communication and language.

06

What researchers measure

Primary outcomes

  1. Mullen Early Learning Scales (MSEL)

    The MSEL provides expressive language scale T-scores. We will compare the changes in T-scores throughout the different time points, expecting improvement throughout each time point.

    Time frame: child's 6,9,12,15,18 and 24 months of age

Secondary outcomes

  1. Parent-Child Interaction (PCX)

    A 15-minute parent-child play-based interaction will be collected at every time point. Expressive language (canonical babble ratio, number of different consonants, vocalizations and number of words), communicative gestures, joint engagement, and object play will be measured and compared at each time point.

    Time frame: child's 6,9,12,15,18 and 24 months of age

  2. LENA

    Parents will collect day-long naturalistic recordings of their child's language environment. We will compare them throughout each time point.

    Time frame: child's 6,9,12,15,18 and 24 months of age

  3. Resting electroencephalogram test (EEG)

    EEG data (L Fronto-Temporal (alpha, gamma)- coherence) will be recorded in the participants' home. They will be compared at the distinct time frames they are collected.

    Time frame: child's 6,9,12 months of age

Other outcomes

  1. Autism Diagnostic Observation Schedule-2 (ADOS-2)

    At 24 months the ADOS (Mod 1 and 2) will be administered to determine diagnosis of autism.

    Time frame: 24 months of age

07

Study locations

2 of 2 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Dec 2027, 37 months after the start.

Of 354 non-industry interventional studies with no phase under Autistic Disorder, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 52. This study's planned 37 months is above that.

Counting every sponsor, half of 366 studies reached it within 26 months; a quarter within 13 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 25, 2023
First posted
May 11, 2023
StartActual
Nov 25, 2024
Primary completionEst.
Dec 31, 2027
CompletionEst.
Jun 30, 2028
Last update
Mar 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05853861
Responsible party
Connie Kasari, Ph.D. (Professor/PhD, University of California, Los Angeles) — Principal investigator
First posted
May 11, 2023
Start date
Nov 25, 2024
Primary completion
Dec 31, 2027 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Mar 31, 2026

Study contacts

Connie Kasari, PhD
Contact
kasari@gseis.ucla.edu
310-825-8342
Consuelo Garcia, BS
Contact
cogarcia@mednet.ucla.edu
562-301-6141

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion